Effect of LBH589 and/or AMN107 on percentage of nonviable primary CML cells
Patient sample . | Control . | AMN107, 50 nM . | AMN107, 100 nM . | LBH589, 20 nM . | LBH589, 50 nM . | 50 nM AMN107 + 50 nM LBH589 . | 100 nM AMN107 + 50 nM LBH589 . |
|---|---|---|---|---|---|---|---|
| 1 | 2.3 | 8.5 | 16.8 | 4.8 | 32.9 | 46.5 | 48.6 |
| 2 | 11.2 | 24.7 | 32.4 | 17.2 | 28.5 | 47.0 | ND |
| 3 | 7.1 | 29.0 | 44.0 | 39.0 | 56.0 | 62.0 | 63.0 |
| 4 | 9.6 | 30.7 | 35.8 | 16.5 | 28.6 | 42.6 | 49.2 |
| 5 | 2.2 | 18.6 | 29.0 | 22.8 | 38.6 | 58.9 | 67.6 |
| 6 | 5.0 | 10.8 | 23.0 | 34.6 | 60.1 | 69.4 | 68.8 |
| 7 | 8.0 | 10.6 | 22.4 | 24.6 | 51.0 | 58.1 | 62.9 |
| Mean ± SEM | 6.5 ± 1.2 | 19.0 ± 3.3 | 29.1 ± 3.2 | 22.8 ± 4.0 | 42.2 ± 4.7 | 54.9 ± 3.4* | 60.0 ± 3.1* |
| 8† | 9.5 | 12.1 | 10.5 | 23.5 | 37.8 | 38.1 | 38.0 |
| 9† | 16.0 | 17.5 | 16.4 | 28.8 | 42.0 | 42.9 | 43.0 |
| 10† | 15.0 | 13.8 | 14.7 | 35.9 | 47.4 | 47.6 | 46.2 |
| Mean ± SEM | 13.5 ± 1.7 | 14.5 ± 1.3 | 13.9 ± 1.4 | 29.4 ± 2.9 | 42.2 ± 2.3 | 42.9 ± 2.2‡ | 42.4 ± 1.9‡ |
Patient sample . | Control . | AMN107, 50 nM . | AMN107, 100 nM . | LBH589, 20 nM . | LBH589, 50 nM . | 50 nM AMN107 + 50 nM LBH589 . | 100 nM AMN107 + 50 nM LBH589 . |
|---|---|---|---|---|---|---|---|
| 1 | 2.3 | 8.5 | 16.8 | 4.8 | 32.9 | 46.5 | 48.6 |
| 2 | 11.2 | 24.7 | 32.4 | 17.2 | 28.5 | 47.0 | ND |
| 3 | 7.1 | 29.0 | 44.0 | 39.0 | 56.0 | 62.0 | 63.0 |
| 4 | 9.6 | 30.7 | 35.8 | 16.5 | 28.6 | 42.6 | 49.2 |
| 5 | 2.2 | 18.6 | 29.0 | 22.8 | 38.6 | 58.9 | 67.6 |
| 6 | 5.0 | 10.8 | 23.0 | 34.6 | 60.1 | 69.4 | 68.8 |
| 7 | 8.0 | 10.6 | 22.4 | 24.6 | 51.0 | 58.1 | 62.9 |
| Mean ± SEM | 6.5 ± 1.2 | 19.0 ± 3.3 | 29.1 ± 3.2 | 22.8 ± 4.0 | 42.2 ± 4.7 | 54.9 ± 3.4* | 60.0 ± 3.1* |
| 8† | 9.5 | 12.1 | 10.5 | 23.5 | 37.8 | 38.1 | 38.0 |
| 9† | 16.0 | 17.5 | 16.4 | 28.8 | 42.0 | 42.9 | 43.0 |
| 10† | 15.0 | 13.8 | 14.7 | 35.9 | 47.4 | 47.6 | 46.2 |
| Mean ± SEM | 13.5 ± 1.7 | 14.5 ± 1.3 | 13.9 ± 1.4 | 29.4 ± 2.9 | 42.2 ± 2.3 | 42.9 ± 2.2‡ | 42.4 ± 1.9‡ |
Samples of primary, IM refractory CML-BC cells, including 3 samples with expression of Bcr-AblT315I mutation (samples 8, 9, and 10), were treated with the indicated concentrations of LBH589 and/or AMN107 for 48 hours, and the percentage of nonviable cells was determined by the trypan blue exclusion method. The values represent mean of 2 experiments performed in duplicate.
ND represents treatment not studied.
Values significantly greater than those following treatment with either agent alone at the indicated concentrations (P < .05).
Samples with expression of Bcr-AblT315I.
Values not significantly different than those following treatment with 50 nM LBH589 alone (P > .05).